As for the therapeutic application of CAR-T cell therapy in HER2-positive breast cancer, although HER2-targeted CAR can effectively produce an antitumor effect on HER-2-positive breast cancer, the off-target effects in clinical research remains a difficult problem. This evidence concerns the gene ERBB2 and breast carcinoma.